ReviewNeuroendocrinology2026
Is Hypothalamic Dysfunction a Cause of Type II Diabetes Mellitus?
Review in Neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Background: A number of factors contribute to the development of diabetes mellitus (DM), but until recently, the role of hypothalamic dysfunction in the development of this disorder has not received sufficient attention. Hypothalamic neurons that project to the autonomic nervous system control overall glucose metabolism and insulin sensitivity. These neurons, in turn, are controlled by specialized astrocytes possessing proteins that enable them to function as nutrient sensors for glucose and fatty acids. An aging-related pathological process (that of mitochondrial degeneration) is present in these specific hypothalamic astrocytes. This mitochondrial degeneration can be accelerated by access to a high-fat diet, which also induces hypothalamic resistance to leptin, generalized insulin resistance, and an abnormal glucose homeostasis. An impaired astrocyte-neuron signaling, caused by this pathological mitochondrial degeneration, may underlie an abnormal hypothalamic function that leads to the development of type II diabetes. Pharmacological agents that protect astrocytes from mitochondrial degeneration may have a place in the treatment of type II diabetes. Summary: This article reviews evidence that hypothalamic pathology may make an important contribution to the etiology of type II DM. Key Messages: Abnormalities in hypothalamic astrocytes provoke a disturbed hypothalamic function that contributes to the development of DM. </p>.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.